Special Issue "Epigenetic Control of B-Cell Lymphomagenesis and Response to Therapy"

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".

Deadline for manuscript submissions: 15 December 2021.

Special Issue Editor

Dr. Gael Roue
E-Mail Website
Guest Editor
Experimental and Clinical Hematology Program, Josep Carreras Leukaemia Research Institute, 08916 Badalona, Spain
Interests: B-cell non-Hodgkin lymphoma; tumor modeling; tumor microenvironment; protein homeostasis; targeted therapy; epigenetic drugs

Special Issue Information

Dear Colleagues,

The term B-cell lymphoma encompasses different neoplasms characterized by an abnormal proliferation of lymphoid cells at various stages of differentiation. B-cell lymphoma develops more frequently in older adults and immunocompromised individuals and includes both Hodgkin’s lymphomas (HLs) and most B-cell non-Hodgkin lymphomas (B-NHLs). Thanks to the recent advances in deep sequencing, it has become apparent that mutations affecting histone methyltransferases, histone demethylases, histone acetyltransferases, and consequent disturbance of epigenomic patterning are frequent events in most B-cell lymphomas.

In this Special Issue, we welcome both review articles and original research aimed at highlighting these new findings and providing a conceptual framework for understanding how epigenetic lesions contribute to lymphomagenesis and to response to therapy. We look forward to your contribution.

Dr. Gael Roue
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Non-Hodgkin lymphoma
  • Epigenetics
  • DNA methylation
  • HAT
  • HDAC
  • EZH2
  • Bromodomain inhibitors
  • Drug combination
  • Clinical testing

Published Papers

This special issue is now open for submission.
Back to TopTop